Eurofins Scientific has patented a method for producing peptides aimed at treating, monitoring, or diagnosing diseases. The process involves analyzing genomic and RNA data, identifying disease-specific mutations, and evaluating associated epitopes to generate peptides tailored to the subject’s MHC type and disease profile. GlobalData’s report on Eurofins Scientific gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Eurofins Scientific, Telomerase reverse transcriptase screening was a key innovation area identified from patents. Eurofins Scientific's grant share as of July 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Method for producing disease-specific peptides using genomic analysis
The granted patent US12065699B2 outlines a comprehensive method and apparatus for producing peptides aimed at treating, monitoring, or diagnosing diseases in subjects. The method begins with the input of information related to mutations specific to diseased tissues and the subject's MHC type into an analyzer. This involves sequencing the subject's genome and RNA to identify mutations and expression levels. The analyzer then assesses epitopes associated with these mutations, utilizing a reference database to annotate candidate mutations. This process includes converting nucleic acid information into amino acid sequences to generate wild-type (WT) and mutant (MT) peptides, followed by a ranking of epitopes based on various criteria, including IC50 values and the number of hits from epitope and mutation searching software.
Additionally, the patent describes an apparatus that incorporates a non-transitory computer-readable medium, which includes an information inputting unit for sequencing and analyzing the subject's genome and RNA. The epitope analyzing unit further processes the data to identify and rank epitopes, ultimately leading to the production of peptides based on the output list. The apparatus also features capabilities for MHC typing and integrates multiple analytical steps to ensure a comprehensive approach to peptide identification. This innovative method and apparatus aim to enhance the precision of peptide-based therapies and diagnostics in the context of personalized medicine.
To know more about GlobalData’s detailed insights on Eurofins Scientific, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
